Login
$ACRS
$3.66 +$0.05 (1.52%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Neal Walker Also a director
CEO
Title from the Form 4 dated Feb 3, 2026
56 Not stated Not stated $3,375,591
Kevin Balthaser
Chief Financial Officer
39 Since 2023
3 years
2017 $1,490,790
Hugh Davis, Ph.D. Also a director
President and COO
Title from the Form 4 dated Feb 3, 2026
67 Not stated Not stated Not reported
Jesse Hall
Chief Medical Officer
52 Since 2025
1 year
Not stated Not reported
Roland Kolbeck
Chief Scientific Officer
62 Since 2025
1 year
Not stated Not reported
James Loerop
Chief Business Officer
62 Since 2022
4 years
Not stated $1,447,106

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
8.3 years
from year joined
CEO also chairs the board
Yes
Neal Walker
Director Age On board Independent Committees Other public boards Pay Source
Neal Walker
56 Not stated Not independent None stated Aldeyra Therapeutics, Inc. Paid as CEO
Christopher Molineaux
60 2014
12 years
Independent None stated None stated Not stated
Hugh Davis, Ph.D.
67 2024
2 years
Not independent None stated None stated Not stated
Anand Mehra, M.D.
50 2014
12 years
Independent None stated None stated Not stated
Maxine Gowen, Ph.D.
68 2019
7 years
Independent None stated Passage Bio, Inc. Not stated
Vincent Milano
62 2020
6 years
Independent
Audit · Chair
BioCryst Pharmaceuticals, Inc. Not stated
Andrew Schiff, M.D.
60 2017
9 years
Independent None stated Monte Rosa Therapeutics, Inc. Not stated
William Humphries
59 2016
10 years
Independent None stated Clearside Biomedical, Inc. Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 23, 2026
Anand Mehra
a member of our Board
$1.5 million
November 2024

Purchased 666,666 shares of common stock at $2.25 per share in a private placement.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support